Cargando…

Immunogenicity of Virus Like Particle Forming Baculoviral DNA Vaccine against Pandemic Influenza H1N1

An outbreak of influenza H1N1 in 2009, representing the first influenza pandemic of the 21st century, was transmitted to over a million individuals and claimed 18,449 lives. The current status in many countries is to prepare influenza vaccine using cell-based or egg-based killed vaccine. However, tr...

Descripción completa

Detalles Bibliográficos
Autores principales: Gwon, Yong-Dae, Kim, Sehyun, Cho, Yeondong, Heo, Yoonki, Cho, Hansam, Park, Kihoon, Lee, Hee-Jung, Choi, Jiwon, Poo, Haryoung, Kim, Young Bong
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Public Library of Science 2016
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4858234/
https://www.ncbi.nlm.nih.gov/pubmed/27149064
http://dx.doi.org/10.1371/journal.pone.0154824
_version_ 1782430776853266432
author Gwon, Yong-Dae
Kim, Sehyun
Cho, Yeondong
Heo, Yoonki
Cho, Hansam
Park, Kihoon
Lee, Hee-Jung
Choi, Jiwon
Poo, Haryoung
Kim, Young Bong
author_facet Gwon, Yong-Dae
Kim, Sehyun
Cho, Yeondong
Heo, Yoonki
Cho, Hansam
Park, Kihoon
Lee, Hee-Jung
Choi, Jiwon
Poo, Haryoung
Kim, Young Bong
author_sort Gwon, Yong-Dae
collection PubMed
description An outbreak of influenza H1N1 in 2009, representing the first influenza pandemic of the 21st century, was transmitted to over a million individuals and claimed 18,449 lives. The current status in many countries is to prepare influenza vaccine using cell-based or egg-based killed vaccine. However, traditional influenza vaccine platforms have several limitations. To overcome these limitations, many researchers have tried various approaches to develop alternative production platforms. One of the alternative approach, we reported the efficacy of influenza HA vaccination using a baculoviral DNA vaccine (AcHERV-HA). However, the immune response elicited by the AcHERV-HA vaccine, which only targets the HA antigen, was lower than that of the commercial killed vaccine. To overcome the limitations of this previous vaccine, we constructed a human endogenous retrovirus (HERV) envelope-coated, baculovirus-based, virus-like-particle (VLP)–forming DNA vaccine (termed AcHERV-VLP) against pandemic influenza A/California/04/2009 (pH1N1). BALB/c mice immunized with AcHERV-VLP (1×10(7) FFU AcHERV-VLP, i.m.) and compared with mice immunized with the killed vaccine or mice immunized with AcHERV-HA. As a result, AcHERV-VLP immunization produced a greater humoral immune response and exhibited neutralizing activity with an intrasubgroup H1 strain (PR8), elicited neutralizing antibody production, a high level of interferon-γ secretion in splenocytes, and diminished virus shedding in the lung after challenge with a lethal dose of influenza virus. In conclusion, VLP-forming baculovirus DNA vaccine could be a potential vaccine candidate capable of efficiently delivering DNA to the vaccinee and VLP forming DNA eliciting stronger immunogenicity than egg-based killed vaccines.
format Online
Article
Text
id pubmed-4858234
institution National Center for Biotechnology Information
language English
publishDate 2016
publisher Public Library of Science
record_format MEDLINE/PubMed
spelling pubmed-48582342016-05-13 Immunogenicity of Virus Like Particle Forming Baculoviral DNA Vaccine against Pandemic Influenza H1N1 Gwon, Yong-Dae Kim, Sehyun Cho, Yeondong Heo, Yoonki Cho, Hansam Park, Kihoon Lee, Hee-Jung Choi, Jiwon Poo, Haryoung Kim, Young Bong PLoS One Research Article An outbreak of influenza H1N1 in 2009, representing the first influenza pandemic of the 21st century, was transmitted to over a million individuals and claimed 18,449 lives. The current status in many countries is to prepare influenza vaccine using cell-based or egg-based killed vaccine. However, traditional influenza vaccine platforms have several limitations. To overcome these limitations, many researchers have tried various approaches to develop alternative production platforms. One of the alternative approach, we reported the efficacy of influenza HA vaccination using a baculoviral DNA vaccine (AcHERV-HA). However, the immune response elicited by the AcHERV-HA vaccine, which only targets the HA antigen, was lower than that of the commercial killed vaccine. To overcome the limitations of this previous vaccine, we constructed a human endogenous retrovirus (HERV) envelope-coated, baculovirus-based, virus-like-particle (VLP)–forming DNA vaccine (termed AcHERV-VLP) against pandemic influenza A/California/04/2009 (pH1N1). BALB/c mice immunized with AcHERV-VLP (1×10(7) FFU AcHERV-VLP, i.m.) and compared with mice immunized with the killed vaccine or mice immunized with AcHERV-HA. As a result, AcHERV-VLP immunization produced a greater humoral immune response and exhibited neutralizing activity with an intrasubgroup H1 strain (PR8), elicited neutralizing antibody production, a high level of interferon-γ secretion in splenocytes, and diminished virus shedding in the lung after challenge with a lethal dose of influenza virus. In conclusion, VLP-forming baculovirus DNA vaccine could be a potential vaccine candidate capable of efficiently delivering DNA to the vaccinee and VLP forming DNA eliciting stronger immunogenicity than egg-based killed vaccines. Public Library of Science 2016-05-05 /pmc/articles/PMC4858234/ /pubmed/27149064 http://dx.doi.org/10.1371/journal.pone.0154824 Text en © 2016 Gwon et al http://creativecommons.org/licenses/by/4.0/ This is an open access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0/) , which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
spellingShingle Research Article
Gwon, Yong-Dae
Kim, Sehyun
Cho, Yeondong
Heo, Yoonki
Cho, Hansam
Park, Kihoon
Lee, Hee-Jung
Choi, Jiwon
Poo, Haryoung
Kim, Young Bong
Immunogenicity of Virus Like Particle Forming Baculoviral DNA Vaccine against Pandemic Influenza H1N1
title Immunogenicity of Virus Like Particle Forming Baculoviral DNA Vaccine against Pandemic Influenza H1N1
title_full Immunogenicity of Virus Like Particle Forming Baculoviral DNA Vaccine against Pandemic Influenza H1N1
title_fullStr Immunogenicity of Virus Like Particle Forming Baculoviral DNA Vaccine against Pandemic Influenza H1N1
title_full_unstemmed Immunogenicity of Virus Like Particle Forming Baculoviral DNA Vaccine against Pandemic Influenza H1N1
title_short Immunogenicity of Virus Like Particle Forming Baculoviral DNA Vaccine against Pandemic Influenza H1N1
title_sort immunogenicity of virus like particle forming baculoviral dna vaccine against pandemic influenza h1n1
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4858234/
https://www.ncbi.nlm.nih.gov/pubmed/27149064
http://dx.doi.org/10.1371/journal.pone.0154824
work_keys_str_mv AT gwonyongdae immunogenicityofviruslikeparticleformingbaculoviraldnavaccineagainstpandemicinfluenzah1n1
AT kimsehyun immunogenicityofviruslikeparticleformingbaculoviraldnavaccineagainstpandemicinfluenzah1n1
AT choyeondong immunogenicityofviruslikeparticleformingbaculoviraldnavaccineagainstpandemicinfluenzah1n1
AT heoyoonki immunogenicityofviruslikeparticleformingbaculoviraldnavaccineagainstpandemicinfluenzah1n1
AT chohansam immunogenicityofviruslikeparticleformingbaculoviraldnavaccineagainstpandemicinfluenzah1n1
AT parkkihoon immunogenicityofviruslikeparticleformingbaculoviraldnavaccineagainstpandemicinfluenzah1n1
AT leeheejung immunogenicityofviruslikeparticleformingbaculoviraldnavaccineagainstpandemicinfluenzah1n1
AT choijiwon immunogenicityofviruslikeparticleformingbaculoviraldnavaccineagainstpandemicinfluenzah1n1
AT pooharyoung immunogenicityofviruslikeparticleformingbaculoviraldnavaccineagainstpandemicinfluenzah1n1
AT kimyoungbong immunogenicityofviruslikeparticleformingbaculoviraldnavaccineagainstpandemicinfluenzah1n1